INmune Bio
INMB
35 hedge funds and large institutions have $11.7M invested in INmune Bio in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 3 closing their positions.
1,150% more call options, than puts
Call options by funds: $175K | Put options by funds: $14K
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
14% more capital invested
Capital invested by funds: $10.3M → $11.7M (+$1.42M)
3% more funds holding
Funds holding: 34 → 35 (+1)
0.89% more ownership
Funds ownership: 9.18% → 10.07% (+0.89%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QCG
Quadrant Capital Group
Cincinnati,
Ohio
|
+$483K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$454K |
| 3 |
Renaissance Technologies
New York
|
+$280K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$158K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FA
Fermata Advisors
Sonoma,
California
|
-$156K |
| 2 |
SC
Sepio Capital
Salt Lake City,
Utah
|
-$147K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$34K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$26.7K |
| 5 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$17.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $13K | -$5.37K | -667 | -24% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $13K | +$4.3K | +534 | +36% |
|
|
VNA
28
Valley National Advisers
Bethlehem,
Pennsylvania
| $8K | – | – | – |
|
|
ADL
29
Asset Dedication LLC
San Francisco,
California
| $5K | – | – | – |
|
|
CA
30
Clearstead Advisors
Cleveland,
Ohio
| $2.71K | +$3.38K | +420 | New |
|
|
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2.58K | – | – | – |
|
|
IA
32
IFP Advisors
Tampa,
Florida
| $1.47K | -$1.48K | -184 | -50% |
|
33
Fidelity Investments
Boston,
Massachusetts
| $594 | +$668 | +83 | +922% |
|
|
ASN
34
Advisory Services Network
Atlanta,
Georgia
| $581 | – | – | – |
|
|
FA
35
Fermata Advisors
Sonoma,
California
| – | -$156K | -24,611 | Closed |
|
|
SC
36
Sepio Capital
Salt Lake City,
Utah
| – | -$147K | -23,200 | Closed |
|
|
CM
37
Caption Management
Oklahoma City,
Oklahoma
| – | -$4.37K | -689 | Closed |
|
INMB Hedge Fund Activity: Q1 2023 in Review
35 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q1 2023, worth a combined $11.7M — up 14% from $10.3M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new INMB positions and 3 closed out — a net gain of 2 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Quadrant Capital Group, opening a new position worth an estimated $483K. The largest seller was Fermata Advisors, exiting entirely with an estimated $156K sold.
- 35 institutional investors held INmune Bio (INMB) as of Q1 2023, up from 34 in Q4 2022.
- Funds reported $11.7M of INmune Bio stock for Q1 2023, up 14% quarter-over-quarter.
- 5 funds opened new INmune Bio positions in Q1 2023 and 3 closed out, a net change of +2 holders.
- The largest INmune Bio buyer in Q1 2023 was Quadrant Capital Group, an estimated $483K added.
- The largest INmune Bio seller in Q1 2023 was Fermata Advisors, an estimated $156K sold.
Based on aggregated 13F filings for Q1 2023.